維亞生物(01873.HK):建議更新一般授權以配發及發行股份
格隆匯 1 月 4日丨維亞生物(01873.HK)公佈,董事會建議更新現有一般授權,以讓董事(i)配發及發行不超過公司於股東特別大會上通過相關決議案之日已發行股本總數20%的新股份以及(ii)擴大更新一般授權至公司購回的股份。根據上市規則第13.36(4)條,更新一般授權須待公司股東大會上獲獨立股東的批准。
截至公吿日期,公司擁有合共1,917,880,747股已發行在外股份。待股東特別大會上通過普通決議案以批准更新一般授權並假設公司自公吿日期至股東特別大會日期之間不再發行及╱或購回任何股份,根據更新一般授權,公司將獲准配發及發行383,576,149股股份,即於公吿日期已發行股份總數的20%。
截至公吿日期,公司已根據現有一般授權以配售方式發行1.30億股股份,籌集了所得款項淨額約10.51億港元,公司亦已發行有擔保可轉換債券2.80億美元,可按初步轉換價每股11.6370港元轉換為186,519,893股股份。合併計算,公司已根據其現有一般授權發行或同意發行最多316,519,893股股份。
公吿稱,集團為綜合性藥物發現平台,並已動用其絕大部分現有一般授權。考慮到公司的下屆股東周年大會僅可能於2021年6月舉行,董事會建議於股東特別大會上尋求獨立股東批准更新一般授權,以便於出現資金需求或獲提供有吸引力的投資條款時為公司提供更大的融資靈活性。更新一般授權將使公司能夠於目前至下屆股東周年大會之間的市場狀況及出現投資機會時迅速作出應對,提供更有效的資金籌集流程,並避免於公司進行此類有關交易時由於未及時獲得特定授權而可能導致的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.